Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality
Open Access
- 6 December 2017
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 103 (2), 202-205
- https://doi.org/10.1002/cpt.946
Abstract
The role of real-world evidence (RWE) in regulatory, drug development, and healthcare decision-making is rapidly expanding. Recent advances have increased the complexity of cancer care and widened the gap between randomized clinical trial (RCT) results and the evidence needed for real-world clinical decisions. Instead of remaining invisible, data from the >95% of cancer patients treated outside of clinical trials can help fill this void.This publication has 4 references indexed in Scilit:
- Real-world Data for Clinical Evidence Generation in OncologyJNCI Journal of the National Cancer Institute, 2017
- Accelerating development of scientific evidence for medical products within the existing US regulatory frameworkNature Reviews Drug Discovery, 2017
- From big data to smart data: FDA's INFORMED initiativeNature Reviews Drug Discovery, 2017
- Opportunities and Challenges in Leveraging Electronic Health Record Data in OncologyFuture Oncology, 2016